glp1
MariTide (maridebart cafraglutide) tracker
Educational reference for MariTide (maridebart cafraglutide). Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
504 h
Tmax
—
Category
glp1
Also known as: maridebart-cafraglutide, amg-133
MariTide is an investigational GIP antagonist and GLP-1 agonist conjugate.
Mechanism
An investigational antibody-peptide conjugate that antagonizes the GIP receptor while activating the GLP-1 receptor.
Research summary
Studied in phase 1 and phase 2 obesity trials with less frequent dosing than weekly agents. Not FDA-approved.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- MariTide phase 1 first-in-human study · Nature Metabolism (per secondary reports)Half-life reported by the sponsor and secondary summaries as about 21 days (~504 h); the primary PK table was not independently verified.
TrackPep adalah aplikasi pencatatan. Aplikasi ini merekam apa yang Anda catat dan tidak pernah merekomendasikan atau menghitung jumlahnya.